Claritev (NYSE:CTEV – Get Free Report) and OneMedNet (NASDAQ:ONMD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.
Analyst Ratings
This is a summary of recent ratings and price targets for Claritev and OneMedNet, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Claritev | 1 | 2 | 6 | 0 | 2.56 |
| OneMedNet | 1 | 0 | 0 | 0 | 1.00 |
Claritev currently has a consensus target price of $44.83, indicating a potential upside of 66.73%. Given Claritev’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Claritev is more favorable than OneMedNet.
Volatility & Risk
Claritev has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, OneMedNet has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
Profitability
This table compares Claritev and OneMedNet’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Claritev | -27.05% | N/A | -5.74% |
| OneMedNet | -584.20% | N/A | -521.20% |
Institutional and Insider Ownership
87.2% of Claritev shares are held by institutional investors. Comparatively, 0.9% of OneMedNet shares are held by institutional investors. 7.4% of Claritev shares are held by insiders. Comparatively, 50.2% of OneMedNet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Claritev and OneMedNet”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Claritev | $965.41 million | 0.47 | -$284.28 million | ($16.42) | -1.64 |
| OneMedNet | $1.36 million | 23.28 | -$2.80 million | ($1.60) | -3.34 |
OneMedNet has lower revenue, but higher earnings than Claritev. OneMedNet is trading at a lower price-to-earnings ratio than Claritev, indicating that it is currently the more affordable of the two stocks.
Summary
Claritev beats OneMedNet on 8 of the 13 factors compared between the two stocks.
About Claritev
Claritev, formerly known as MultiPlan, provides technology-enabled services intended to help manage healthcare costs and support payment accuracy. Its offerings include access to provider networks, claims and payment solutions, and data analytics for evaluating healthcare costs and utilization. The company serves health plans, self-insured employers, third-party administrators and other participants in the U.S. healthcare system. Its services are designed to help customers identify cost-management opportunities and support more efficient healthcare transactions.
About OneMedNet
OneMedNet Corporation provides real-world data (RWD) for healthcare research. Through its iRWD platform, the company helps connect healthcare organizations that contribute medical information with pharmaceutical, biotechnology and medical-device companies seeking data for research and product development. Its offerings include curated, de-identified clinical records and medical imaging data. These datasets can support activities such as clinical research and the evaluation of medicines and medical devices, while the platform is designed to facilitate secure data access and collaboration.
Receive News & Ratings for Claritev Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Claritev and related companies with MarketBeat.com's FREE daily email newsletter.
